Ian Flinn, MD

Articles

Dr. Flinn on the FDA Approval of Duvelisib in CLL and Follicular Lymphoma

September 25th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma

July 11th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

Dr. Flinn Discusses Hu5F9-G4 Plus Rituximab in NHL

June 12th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses Hu5F9-G4 (5F9) plus rituximab (Rituxan) in patients with non-Hodgkin lymphoma.

Dr. Flinn on Toxicities With Venetoclax Plus Obinutuzumab in CLL

February 14th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the toxicities associated with the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

Dr. Flinn on Next Steps With Venetoclax Plus Obinutuzumab in CLL

January 6th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Dr. Flinn on Venetoclax and Obinutuzumab in CLL

December 12th 2017

Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting. Overall, 32 patients were treated with this combination in the first-line setting. Investigators saw high complete remission (CR) rates, with over two-thirds of patients experiencing a CR, Flinn explains. In addition, high MRD negativity rates were also demonstrated, in both the peripheral blood and the bone marrow.